779 reports of this reaction
5.3% of all ELACESTRANT reports
#3 most reported adverse reaction
DISEASE PROGRESSION is the #3 most commonly reported adverse reaction for ELACESTRANT, manufactured by Stemline Therapeutics, Inc.. There are 779 FDA adverse event reports linking ELACESTRANT to DISEASE PROGRESSION. This represents approximately 5.3% of all 14,750 adverse event reports for this drug.
Patients taking ELACESTRANT who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is moderately reported among ELACESTRANT users, representing a notable but not dominant share of adverse events.
In addition to disease progression, the following adverse reactions have been reported for ELACESTRANT:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 779 FDA reports for ELACESTRANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 5.3% of all adverse event reports for ELACESTRANT, making it one of the most commonly reported side effect.
If you experience disease progression while taking ELACESTRANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.